Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Pediatric Immunology

Building Your Care Team: Specialists and Advocacy

At a Glance

Children with RALD often need coordinated care from a pediatric immunologist, hematologist-oncologist, and medical geneticist. Families can support care by keeping complete records, seeking national expert input, and discussing voluntary patient registry participation with their medical team.

Because RAS-associated autoimmune leukoproliferative disease (RALD) is exceptionally rare, your child’s care cannot rest on the shoulders of a single doctor. Managing a disease with this few documented cases requires a multidisciplinary team—a group of specialists who pool their expertise to monitor your child’s unique needs [1][2].

As a parent or caregiver, you are the most important member of this team. You are the “keeper of the record” and the primary advocate who ensures your local doctors have access to the complete history.

The Core Specialists

A robust care team for RALD typically includes three primary specialists working in tandem:

  • Pediatric Immunologist: They focus on the underlying immune dysregulation, managing the risk of infections, and monitoring for signs that the immune system is attacking the body (autoimmunity) [3][4].
  • Pediatric Hematologist-Oncologist: This specialist manages blood counts and monitors the spleen and liver. Because RALD can overlap with blood disorders like JMML, the hematologist is essential for long-term surveillance [5][6].
  • Medical Geneticist: This expert interprets the complex somatic mutations found in the NRAS or KRAS genes. They help determine the exact mutation profile and provide guidance on family risk [7][8].

You may also need to consult with pharmacists (for medication management), social workers (for school and psychological support), or infectious disease specialists [9][10].

Preparing Your “Second-Opinion Packet”

Because most local doctors will have never seen a case of RALD, you should arrive at every first appointment with an organized history. This allows a new specialist to get up to speed quickly [2]. Your packet should include:

  1. Genetic Test Results: The full report showing the specific NRAS or KRAS mutation, including the “variant allele fraction” (VAF—how much of the mutation was found) and in which cells it was found [6][8].
  2. A CBC Chronology: A simple table of your child’s Complete Blood Counts over the last several months, highlighting trends in monocytes, platelets, and red blood cells [11].
  3. Flow Cytometry Reports: If available, bring reports showing T-cell populations. While elevated double-negative T cells (DNTs) are a hallmark of classic ALPS, they are just one contextual data point in RALD [12][13].
  4. Imaging Reports: Results from ultrasounds measuring the size of the spleen and liver [10].
  5. Current Medication List: Exact dosages of all immunosuppressants, antibiotics, and supplements.

Bridging the Gap to National Experts

For a disease this rare, your local team should be willing to collaborate with national centers that specialize in immune dysregulation and ALPS-like disorders [14].

Don’t be afraid to ask your local doctor to present your child’s case at an immunology/hematology case conference. Many specialists welcome the opportunity to consult with world-class experts at major children’s research hospitals [2][1].

Registry Participation

Because so little is known about the long-term outlook for RALD, you may want to ask your treating institution about enrolling in a patient registry (like the ESID registry) [15][16]. Participation is completely voluntary and requires a strict consent and data privacy process handled by your medical team. Registries allow researchers to study data from many patients at once, helping to develop better guidelines for the future.

Common questions in this guide

Which specialists should be on my child’s RALD care team?
A pediatric immunologist, pediatric hematologist-oncologist, and medical geneticist are the core specialists. The immunologist addresses immune problems and infection risk, the hematologist-oncologist monitors blood counts and the spleen and liver, and the geneticist interprets NRAS or KRAS findings. Infectious disease clinicians, pharmacists, or social workers may also help.
What records should I bring to a RALD second-opinion visit?
Bring the complete NRAS or KRAS genetic report, including the variant allele fraction and the cell type tested, plus a timeline of complete blood count results. Also include flow cytometry reports, spleen and liver imaging, and an up-to-date list of medicines, doses, antibiotics, and supplements.
What does variant allele fraction mean in a RALD genetic report?
Variant allele fraction, or VAF, is the proportion of genetic test readings that contain the reported variant. Its meaning depends on the sample and the cells in which the mutation was found, so a medical geneticist should explain the result in context.
Why should our local doctors consult RALD experts?
RALD is exceptionally rare, so many local clinicians may have little direct experience with it. A case conference or consultation with an immune-dysregulation center can help specialists review the findings and coordinate a plan.
Is joining a patient registry required, and what happens to our information?
Registry participation is voluntary and requires a consent process handled by the treating institution. The medical team should explain how data will be protected and used; combining information from many patients can help researchers improve future guidance.
Who should I call if my child develops a fever or new symptom?
Ask the care team to name a first-call contact and explain how to reach them after hours. Keep that information with your child’s records and follow the team’s instructions for fever or other changes.

Get notified when new evidence is published on Dianzani autoimmune lymphoproliferative disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (16)
  1. 1

    Multidisciplinary approach to treating complex immune dysregulation disorders: an adaptive model for institutional implementation.

    Henderson LA, Abraham RS, Ahmed A, et al.

    Frontiers in immunology 2025; (16()):1519955 doi:10.3389/fimmu.2025.1519955.

    PMID: 40124385
  2. 2

    Mapping Out Autoimmunity Control in Primary Immune Regulatory Disorders.

    Farmer JR, Uzel G

    The journal of allergy and clinical immunology. In practice 2021; (9(2)):653-659 doi:10.1016/j.jaip.2020.12.024.

    PMID: 33358993
  3. 3

    Clinical updates in inborn errors of immunity: a focus on the noninfectious clinical manifestations.

    Campbell E, Shaker MS, Williams KW

    Current opinion in pediatrics 2024; (36(2)):228-236 doi:10.1097/MOP.0000000000001331.

    PMID: 38299990
  4. 4

    Multisystem Autoimmune Inflammatory Disease, Including Colitis, Due to Inborn Error of Immunity.

    Malik A, Stringer E, Warner N, et al.

    Pediatrics 2021; (148(5)) doi:10.1542/peds.2021-050614.

    PMID: 34686572
  5. 5

    Immune cytopenias as a continuum in inborn errors of immunity: An in-depth clinical and immunological exploration.

    Zama D, Conti F, Moratti M, et al.

    Immunity, inflammation and disease 2021; (9(2)):583-594 doi:10.1002/iid3.420.

    PMID: 33838017
  6. 6

    Cutaneous involvement in an 8-year-old boy with Ras-associated autoimmune leucoproliferative disorder (RALD).

    Giacaman A, Bauzá Alonso A, Salinas Sanz JA, et al.

    Clinical and experimental dermatology 2018; (43(8)):913-916 doi:10.1111/ced.13668.

    PMID: 29908030
  7. 7

    Idiopathic splenomegaly in childhood and the spectrum of RAS-associated lymphoproliferative disease: a case report.

    Blanchard-Rohner G, Ragotte RJ, Junker AK, et al.

    BMC pediatrics 2021; (21(1)):45 doi:10.1186/s12887-021-02508-3.

    PMID: 33472608
  8. 8

    RAS-associated Autoimmune Leukoproliferative disease (RALD) manifested with early-onset SLE-like syndrome: a case series of RALD in Chinese children.

    Wang W, Zhou Y, Zhong L, et al.

    Pediatric rheumatology online journal 2019; (17(1)):55 doi:10.1186/s12969-019-0346-1.

    PMID: 31412876
  9. 9

    Early-onset systemic lupus erythematosus in a patient with an inborn error of immunity caused by a NRAS mutation and treated with telitacicept.

    Kang Z, Zhang L

    Molecular and cellular pediatrics 2025; (12(1)):24 doi:10.1186/s40348-025-00212-1.

    PMID: 41317261
  10. 10

    [Ras-associated autoimmune leukoproliferative disorder: a report of 2 cases and literature review].

    He TY, Li CR, Xia Y, et al.

    Zhonghua er ke za zhi = Chinese journal of pediatrics 2017; (55(11)):853-857 doi:10.3760/cma.j.issn.0578-1310.2017.11.013.

    PMID: 29141318
  11. 11

    Clinical Spectrum of Ras-Associated Autoimmune Leukoproliferative Disorder (RALD).

    Neven Q, Boulanger C, Bruwier A, et al.

    Journal of clinical immunology 2021; (41(1)):51-58 doi:10.1007/s10875-020-00883-7.

    PMID: 33011939
  12. 12

    Severe RAS-Associated Lymphoproliferative Disease Case with Increasing αβ Double-Negative T Cells with Atypical Features.

    Kurita D, Shiba N, Ohya T, et al.

    Journal of clinical immunology 2023; (43(8)):1992-1996 doi:10.1007/s10875-023-01566-9.

    PMID: 37644277
  13. 13

    JMML and RALD (Ras-associated autoimmune leukoproliferative disorder): common genetic etiology yet clinically distinct entities.

    Calvo KR, Price S, Braylan RC, et al.

    Blood 2015; (125(18)):2753-8 doi:10.1182/blood-2014-11-567917.

    PMID: 25691160
  14. 14

    Too much of a good thing: a review of primary immune regulatory disorders.

    Tsilifis C, Slatter MA, Gennery AR

    Frontiers in immunology 2023; (14()):1279201 doi:10.3389/fimmu.2023.1279201.

    PMID: 38022498
  15. 15

    The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity.

    Seidel MG, Kindle G, Gathmann B, et al.

    The journal of allergy and clinical immunology. In practice 2019; (7(6)):1763-1770 doi:10.1016/j.jaip.2019.02.004.

    PMID: 30776527
  16. 16

    Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity.

    Maccari ME, Wolkewitz M, Schwab C, et al.

    The Journal of allergy and clinical immunology 2023; (152(4)):984-996.e10 doi:10.1016/j.jaci.2023.06.015.

    PMID: 37390899

This page is for informational purposes only and does not constitute medical advice. Your child’s treating immunologist, hematologist-oncologist, and geneticist should interpret records and guide care.

Guide contents Dianzani autoimmune lymphoproliferative disease
Research & Literature
05 Looking Ahead